In addition, the complex regulation of mTOR expression during NAFLD/NASH, changing at different stages of the disease; increased in children (38) but reduced in adults (39) difficult the targeting of this pathway as an effective approach to treat disease progression. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatotic liver disease.